ABEONA THERAPEUT. DL-01 (PCJ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ABEONA THERAPEUT. DL-01 (PCJ) has a cash flow conversion efficiency ratio of -0.113x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.95 Million ≈ $-20.99 Million USD) by net assets (€159.22 Million ≈ $186.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PCJ equity to assets ratio to measure how much of total assets are equity-financed.
ABEONA THERAPEUT. DL-01 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ABEONA THERAPEUT. DL-01's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ABEONA THERAPEUT. DL-01 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
ABEONA THERAPEUT. DL-01 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABEONA THERAPEUT. DL-01 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
N/A |
|
China Western Power Industrial Co Ltd
SHE:002630
|
0.072x |
|
Taiga Building Products Ltd.
TO:TBL
|
-0.173x |
|
Selena FM S.A.
WAR:SEL
|
0.139x |
|
Vátryggingafélag Íslands hf
IC:SKAGI
|
0.083x |
|
Guangdong Kitech New Material Holding Co.Ltd.
SHE:300995
|
N/A |
|
Anton Oilfield Services Group
F:5AO
|
0.045x |
|
Eaton Vance Floating Rate Income Closed Fund
NYSE:EFT
|
0.035x |
Annual Cash Flow Conversion Efficiency for ABEONA THERAPEUT. DL-01 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ABEONA THERAPEUT. DL-01 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see how much is ABEONA THERAPEUT. DL-01 worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €159.22 Million ≈ $186.14 Million |
€-76.33 Million ≈ $-89.23 Million |
-0.479x | +62.32% |
| 2024-12-31 | €44.03 Million ≈ $51.48 Million |
€-56.02 Million ≈ $-65.49 Million |
-1.272x | +49.04% |
| 2023-12-31 | €14.83 Million ≈ $17.33 Million |
€-37.01 Million ≈ $-43.27 Million |
-2.496x | -53.63% |
| 2022-12-31 | €26.76 Million ≈ $31.29 Million |
€-43.48 Million ≈ $-50.84 Million |
-1.625x | -4.84% |
| 2021-12-31 | €42.37 Million ≈ $49.53 Million |
€-65.67 Million ≈ $-76.77 Million |
-1.550x | -- |
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more